acide tetrahydro-1,7,8,9-pyranno<2,3-g>indolecarboxylique-2 | 81257-90-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: acide tetrahydro-1,7,8,9-pyranno<2,3-g>indolecarboxylique-2
• 英文别名: 7,8,9-trihydro-pyrano[2,3-g]indole-2-carboxylic acid；7,8-dihydro-9H-pyrano[2,3-g]indole-2-carboxylic acid；1,7,8,9-Tetrahydropyrano[2,3-g]indole-2-carboxylic acid
• CAS: 81257-90-1
• 化学式: C₁₂H₁₁NO₃
• 分子量: 217.224
• InChiKey: DJJRKYNKJQAPHU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  62.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  acide tetrahydro-1,7,8,9-pyranno<2,3-g>indolecarboxylique-2 在 chromium(III) oxide 、 copper(II) oxide 作用下， 以 喹啉 、 甲醇 为溶剂， 反应 79.5h， 生成 tetrahydro-1,7,8,9 pyranno<2,3-g>indolyl-3 N,N-dimethylamine
  参考文献：
  名称：

  Synthèse de pyranno[fetg]吲哚

  摘要：

  叠氮乙酸乙酯与 6-甲酰基色满的反应，然后将所得叠氮化物环化，生成 1,7,8,9-四氢吡喃并[2,3-g]吲哚和 2,3,4,8-四氢吡喃并[3,2] -f]吲哚。描述了这些新三环系统的化学反应性的某些方面。合成的所有产品的结构都是在 1H 核磁共振数据的基础上建立的。

  DOI：

  10.1139/v82-298
• 作为产物：
  描述：

  苯并二氢吡喃-6-甲醛 在 盐酸 、 氢氧化钾 、 氮气 、 水 、 sodium 作用下， 以 甲醇 、 xylene 为溶剂， 反应 14.5h， 生成 acide tetrahydro-1,7,8,9-pyranno<2,3-g>indolecarboxylique-2
  参考文献：
  名称：

  Synthèse de pyranno[fetg]吲哚

  摘要：

  叠氮乙酸乙酯与 6-甲酰基色满的反应，然后将所得叠氮化物环化，生成 1,7,8,9-四氢吡喃并[2,3-g]吲哚和 2,3,4,8-四氢吡喃并[3,2] -f]吲哚。描述了这些新三环系统的化学反应性的某些方面。合成的所有产品的结构都是在 1H 核磁共振数据的基础上建立的。

  DOI：

  10.1139/v82-298

文献信息

• Condensed indoline derivatives and their use as 5HT, in particular 5HT2c, receptor ligands
  申请人：Roffey Richard Anthony Jonathan

  公开号：US20050187282A1

  公开（公告）日：2005-08-25

  A chemical compound of formula (I) wherein R 1 and R 2 are independently selected from hydrogen and alkyl; R 3 is alkyl; R 4 and R 5 are selected from hydrogen and alkyl; R 6 and R 7 are independently selected from hydrogen, halogen, hydroxyl, alkyl, aryl, amino, alkylamino, dialkylamino, alkoxy, aryloxy, alkylthio, alkylsulfoxyl, nitro, carbonitrile, carbo-alkoxy, carbo-aryloxy and carboxyl; and A is a 5- or 6-membered ring optionally containing one or more heteroatoms wherein the atoms of the ring A, other than the unsaturated carbon atoms of the phenyl ring to which the ring A is fused, are saturated or unsaturated, and pharmaceutically acceptable salts, addition compounds and prodrugs thereof; and the use thereof in therapy, particularly as an agonist or antagonist of a 5HT receptor, particularly a 5HT 2C receptor, for instance in the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and particularly for the treatment of obesity.

  化学式（I）的化合物，其中R1和R2分别选自氢和烷基；R3是烷基；R4和R5选自氢和烷基；R6和R7分别选自氢、卤素、羟基、烷基、芳基、氨基、烷基氨基、二烷基氨基、烷氧基、芳氧基、烷基硫基、烷基亚砜基、硝基、氰基、羧酸酯基、羧酸芳酯基和羧基；A是一个含有一个或多个杂原子的5-或6元环，其中环A的原子除了与环A融合的苯环的不饱和碳原子外，可以是饱和的或不饱和的，以及其药学上可接受的盐、加合物和前药；以及其在治疗中的用途，特别是作为5HT受体的激动剂或拮抗剂，特别是5HT2C受体，例如在治疗中枢神经系统疾病；中枢神经系统损伤；心血管疾病；胃肠道疾病；尿崩症和睡眠呼吸暂停症，特别是用于肥胖症的治疗。
• Pyrano-indoles
  申请人：Societe de Recherches Industrielles

  公开号：US04436915A1

  公开（公告）日：1984-03-13

  The present invention relates as new industrial product to a derivative of pyrano-indole chosen from the group constituted by: (i) the pyrano[2,3-g]indoles of general formula: ##STR1## in which: X represents a group ##STR2## (where R is a lower alkyl group, OH, lower alkoxy, tosyloxy, NH.sub.2) or >CH--NR'R" (where R' and R", which are identical or different, each represent H or a lower alkyl); R.sub.1 represents an atom of hydrogen, a lower alkyl group, or COY.sub.1 (where Y.sub.1 is a lower alkyl group, an amino acid group CH.sub.2 CH(COOH) NH.sub.2 or an aminoalkylene group --(CH.sub.2).sub.n --NR'R" in which n is a whole number between 1 and 4 and R' and R" are defined as hereinabove); R.sub.2 represents an atom of hydrogen, or a COY.sub.2 group (where Y.sub.2 is OH or lower alkoxy; R.sub.3 represents an atom of hydrogen, an atom of halogen, a CHO group, lower alkyl, CF.sub.3, (CH.sub.2).sub.n NR'R" or CO--CONR'R" (where n, R' and R" are defined as hereinabove, and R.sub.4 represents an atom of hydrogen, an atom of halogen, an OH group, lower alkyl, lower alkoxy, CF.sub.3 or NR'R" (where R' and R" are defined as hereinabove); (ii) the pyrano[3,2-f]indoles of general formula: ##STR3## where X, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are defined as hereinabove; and (iii) their acid addition salts. The invention also relates to the process for preparing this derivative and to its application in therapeutics.

  本发明涉及一种新的工业产品，即吡喃并吲哚衍生物，选自以下组中：(i) 吡喃并[2,3-g]吲哚的通式为：##STR1##其中：X代表一个基团##STR2##（其中R为低级烷基、OH、低级烷氧基、对甲苯磺酰氧基、NH2）或>CH--NR'R"（其中R'和R"相同或不同，分别代表H或低级烷基）；R1代表氢原子、低级烷基或COY1（其中Y1为低级烷基、氨基酸基团CH2CH(COOH)NH2或氨基亚烷基--(CH2)n--NR'R"，其中n为1至4的整数，R'和R"如上定义）；R2代表氢原子或COY2基团（其中Y2为OH或低级烷氧基）；R3代表氢原子、卤素原子、CHO基团、低级烷基、CF3、(CH2)nNR'R"或CO--CONR'R"（其中n、R'和R"如上定义），以及R4代表氢原子、卤素原子、OH基团、低级烷基、低级烷氧基、CF3或NR'R"（其中R'和R"如上定义）；(ii) 吡喃并[3,2-f]吲哚的通式为：##STR3##其中X、R1、R2、R3和R4如上定义；以及(iii) 它们的酸加成盐。本发明还涉及制备该衍生物的方法及其在治疗学中的应用。
• Parp inhibitors
  申请人：ICOS Corporation

  公开号：US20040087588A1

  公开（公告）日：2004-05-06

  The present invention provides compounds comprising a bicyclic aryl moiety, such as 2H-phthalazin-1-one or derivatives thereof, compositions comprising the same, and methods for producing and using the same. In particular, the present invention provides compounds of the formula: 1 or a pharmaceutically acceptable salt, a hydrate, a solvate, or a prodrug thereof; where Q 1 , Q 2 and Y are those defined herein.

  本发明提供了包含双环芳基基团的化合物，例如2H-萘嗪-1-酮或其衍生物，以及包含这些化合物的组合物，以及制备和使用这些化合物的方法。特别地，本发明提供了式1的化合物：1或其药学上可接受的盐、水合物、溶剂合物或前药；其中Q1、Q2和Y的定义如本文所述。
• Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands
  申请人：Roffey Richard Anthony Jonathan

  公开号：US20050192334A1

  公开（公告）日：2005-09-01

  A chemical compound of formula (I) wherein R 1 and R 2 are independently selected from hydrogen and alkyl; R 3 is alkyl; R 4 and R 5 are selected from hydrogen and alkyl; R 6 and R 7 are independently selected from hydrogen, halogen, hydroxyl, alkyl, aryl, amino, alkylamino, dialkylamino, alkoxy, aryloxy, alkylthio, alkylsulfoxyl, nitro, carbonitrile, carbo-alkoxy, carbo-aryloxy and carboxyl; and A is a 5- or 6-membered ring optionally containing one or more heteroatoms wherein the atoms of the ring A, other than the unsaturated carbon atoms of the phenyl ring to which the ring A is fused, are saturated or unsaturated, and pharmaceutically acceptable salts, addition compounds and prodrugs thereof; and the use thereof in therapy, particularly as an agonist or antagonist of a 5HT receptor, particularly a 5HT 2C receptor, for instance in the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and particularly for the treatment of obesity.

  化学式为（I）的化合物，其中R1和R2独立地选自氢和烷基；R3为烷基；R4和R5选自氢和烷基；R6和R7独立地选自氢、卤素、羟基、烷基、芳基、氨基、烷基氨基、二烷基氨基、烷氧基、芳氧基、烷硫基、烷基亚砜基、硝基、氰基、羧基酯基、芳羧基酯基和羧基；A是一个5-或6-成员环，可选地含有一个或多个杂原子，其中环A的原子除与环A融合的苯环的不饱和碳原子外，均为饱和或不饱和的，以及其药学上可接受的盐、加合物和前药；以及其在治疗中的使用，特别是作为5HT受体的激动剂或拮抗剂，特别是5HT2C受体，例如在中枢神经系统疾病、中枢神经系统损伤、心血管疾病、胃肠道疾病、尿崩症和睡眠呼吸暂停症的治疗中，特别是用于肥胖症的治疗。
• Condensed indoline derivatives and their use as 5HT , in particular 5hHT2c, receptor ligands
  申请人：Roffey Anthony Jonathan Richard

  公开号：US20070105889A1

  公开（公告）日：2007-05-10

  A chemical compound of formula (I) wherein R 1 and R 2 are independently selected from hydrogen and alkyl; R 3 is alkyl; R 4 and R 5 are selected from hydrogen and alkyl; R 6 and R 7 are independently selected from hydrogen, halogen, hydroxyl, alkyl, aryl, amino, alkylamino, dialkylamino, alkoxy, aryloxy, alkylthio, alkylsulfoxyl, nitro, carbonitrile, carbo-alkoxy, carbo-aryloxy and carboxyl; and A is a 5- or 6-membered ring optionally containing one or more heteroatoms wherein the atoms of the ring A, other than the unsaturated carbon atoms of the phenyl ring to which the ring A is fused, are saturated or unsaturated, and pharmaceutically acceptable salts, addition compounds and prodrugs thereof; and the use thereof in therapy, particularly as an agonist or antagonist of a 5HT receptor, particularly a 5HT 2C receptor, for instance in the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and particularly for the treatment of obesity.

  化学式为（I）的化合物，其中R1和R2分别选自氢和烷基；R3为烷基；R4和R5选自氢和烷基；R6和R7分别选自氢、卤素、羟基、烷基、芳基、氨基、烷基氨基、二烷基氨基、烷氧基、芳氧基、烷硫基、烷基亚砜基、硝基、氰基、羧甲氧基、羧芳氧基和羧基；A是一个5或6元环，可以包含一个或多个杂原子，环A的原子，除了与环A融合的苯环的不饱和碳原子外，都是饱和或不饱和的，并且其药物可接受的盐、加成物和前药；以及其在治疗中的应用，特别是作为5HT受体的激动剂或拮抗剂，特别是5HT2C受体，例如在中枢神经系统疾病的治疗中；中枢神经系统损伤；心血管疾病；胃肠道疾病；尿崩症和睡眠呼吸暂停症，特别是用于肥胖症的治疗。